Does Presbyterian Healthcare Services Cover Vyvanse?

What Is Vyvanse and Why Does Coverage Get Complicated?

Vyvanse is a central nervous system stimulant approved by the FDA in 2007 for attention-deficit/hyperactivity disorder in patients aged 6 and older, and in 2015 for moderate-to-severe binge-eating disorder (BED) in adults. The FDA label is maintained at the FDA accessdata portal. Its active moiety, d-amphetamine, is released only after first-pass hepatic metabolism, which is cited as the pharmacokinetic rationale for its lower abuse potential relative to immediate-release amphetamine salts. [1]

Schedule II Status and Its Effect on Insurance Processes

Because Vyvanse is classified as a Schedule II controlled substance under the Controlled Substances Act, insurers treat it differently than non-controlled branded medications. Refill-too-soon edits, quantity limits tied to a 30-day supply cap, and mandatory electronic prior authorization are all triggered by Schedule II status in most pharmacy benefit management (PBM) systems. [2]

Generic Entry in 2023

Lisdexamfetamine dimesylate generics entered the US market in August 2023 following Takeda's patent settlement agreements. The FDA maintains a list of approved generic lisdexamfetamine products at its Orange Book database. [3] Presbyterian Healthcare Services plans that previously required Tier 3 or Tier 4 cost-sharing for the brand may now place the generic at Tier 2, cutting member costs by 30 to 60% in typical plan designs.

ADHD Prevalence and Treatment Context

The CDC estimates that approximately 9.4% of US children aged 2 to 17 have ever received an ADHD diagnosis, and stimulant medications remain the first-line pharmacological treatment recommended in the American Academy of Pediatrics guidelines. [4] For adults, ADHD prevalence is estimated at 4.4% of the US population, and the condition frequently goes untreated due to cost and insurance barriers. [5]

How Presbyterian Healthcare Services Organizes Its Drug Formulary

Presbyterian Healthcare Services is a not-for-profit integrated health system based in Albuquerque, New Mexico, operating both a provider network and Presbyterian Health Plan, a managed-care organization serving commercial, Medicaid (Centennial Care), and Medicare Advantage enrollees across New Mexico.

Formulary Tiers Relevant to Vyvanse

PHS formularies generally use a 4- to 5-tier structure:

• Tier 1: Generic preferred drugs, lowest copay
• Tier 2: Generic non-preferred or preferred brand, moderate copay
• Tier 3: Non-preferred brand, higher copay (most common tier for brand Vyvanse)
• Tier 4: Specialty or high-cost brand, highest copay or coinsurance
• Tier 5 (some plans): Specialty injectable or biologics

Brand Vyvanse most commonly lands at Tier 3 on PHS commercial plans, with a 30-day copay in the $80, $150 range before any manufacturer savings program. Generic lisdexamfetamine may appear at Tier 2, with copays near $30, $60. Medicaid Centennial Care members face much lower or zero cost-sharing once prior authorization is approved.

Quantity Limits and Days-Supply Rules

Most PHS plan designs impose a 30-day supply maximum per dispensing for Schedule II stimulants. Some plans additionally cap the daily dose unit (for example, one 70 mg capsule per day as the maximum covered quantity). If your prescriber writes for a dose above the covered quantity limit, a separate quantity-limit exception is required alongside the standard prior authorization. The FDA-approved maximum dose of Vyvanse for ADHD is 70 mg per day; for BED it is also 70 mg per day. [1]

Prior Authorization Requirements for Vyvanse Under PHS

Prior authorization (PA) is nearly universal for Vyvanse under PHS plans, whether you have the commercial HMO, PPO, or Medicaid managed-care product. The PA process protects the insurer from off-label use and confirms medical necessity.

What Your Prescriber Must Submit

A standard PHS PA request for Vyvanse typically requires:

1. A confirmed diagnosis of ADHD (ICD-10: F90.0, F90.9) or BED (ICD-10: F50.81)
2. Documentation of symptom severity using a validated rating scale such as the Adult ADHD Self-Report Scale (ASRS) or Conners' Rating Scale for pediatric patients
3. Evidence of an adequate trial (usually 4 to 6 weeks at a therapeutic dose) of at least one preferred formulary stimulant, such as mixed amphetamine salts (Adderall generics, Tier 1) or methylphenidate (Tier 1), unless contraindicated
4. The prescribing clinician's NPI number and DEA registration confirming Schedule II prescribing authority
5. The patient's current height, weight, blood pressure, and heart rate (cardiovascular screening per FDA label requirements) [1]

Typical PA Decision Timeline

Under New Mexico law and federal managed-care rules, non-urgent PA decisions must be issued within 3 business days of receipt of a complete request. Urgent or expedited requests (when a delay could seriously jeopardize health) must be decided within 72 hours. Presbyterian Health Plan posts its prior authorization policies at presbyterianhealthplan.com. Confirm current timelines with the plan's pharmacy department, as these can change with annual formulary updates.

Step Therapy: The Most Common Denial Trigger

Step therapy, sometimes called "fail first," requires that members try lower-cost alternatives before the insurer approves the requested medication. For Vyvanse, PHS typically requires documented failure of at least one generic stimulant, either amphetamine-based or methylphenidate-based. A 2023 JAMA study found that step-therapy requirements delay appropriate pharmacotherapy by a median of 21 days in ADHD management programs. [6]

Your prescriber can request a step-therapy exception if:

• The patient previously failed the required alternatives before the current insurance period
• A specific medical contraindication exists (for example, a tic disorder worsened by methylphenidate)
• The patient has BED rather than ADHD, as no other FDA-approved pharmacotherapy for BED is on the PHS formulary

What Vyvanse Actually Costs Under Presbyterian Plans

Cost varies substantially by plan type, the formulary tier assigned, and whether the generic or brand is dispensed.

Commercial Plan Estimates

| Plan Type | Formulary Tier | Estimated 30-Day Copay | |---|---|---| | Brand Vyvanse (PHS commercial HMO) | Tier 3 | $80, $150 | | Generic lisdexamfetamine (PHS commercial HMO) | Tier 2 | $30, $60 | | Brand Vyvanse (PHS PPO, out-of-network pharmacy) | Tier 3 + OON penalty | $150, $250 | | Generic lisdexamfetamine (PHS PPO, in-network) | Tier 2 | $25, $55 |

These are estimates. Your actual copay depends on your specific plan's Summary of Benefits and Coverage document.

Medicaid Centennial Care Cost-Sharing

New Mexico Medicaid (Centennial Care) enrollees managed by Presbyterian Health Plan face nominal or zero copays for approved medications. The Medicaid Drug Rebate Program requires manufacturers to pay rebates that offset formulary costs, which is why net member cost-sharing is lower than in commercial plans. [7] Children under 19 are generally exempt from Medicaid copays entirely under federal law.

Takeda's Savings Card Program

Takeda Pharmaceuticals offers a Vyvanse savings card for commercially insured patients not covered by a government program (Medicare, Medicaid, TRICARE). With the card, eligible patients may pay as little as $30 for a 30-day supply. The savings card is not usable with Medicaid or Medicare Part D. Patients can enroll at Takeda's patient support program site. [8]

What to Do If Presbyterian Denies Your Vyvanse Claim

Denials happen. The most common reasons are:

• Step therapy requirements not yet satisfied
• Missing documentation in the PA request (incomplete ADHD rating scale, no DEA number)
• Dose exceeding the quantity limit without a separate exception
• The patient's diagnosis code not matching an FDA-approved indication

Step 1: Request the Denial Reason in Writing

You are entitled to a written explanation of any adverse coverage decision under federal ACA regulations codified at 45 CFR §147.136. Ask for the specific clinical criteria not met.

Step 2: Internal Appeal

File an internal appeal within 30 days of receiving the denial letter (New Mexico state law timeline for commercial plans; confirm the exact window on your Explanation of Benefits). Your prescriber should submit a letter of medical necessity directly addressing the denial criteria, including peer-reviewed literature supporting Vyvanse over the step-therapy alternatives tried.

A 2019 Annals of Internal Medicine analysis found that roughly 40% of internal insurance appeals for specialty medications are overturned when accompanied by adequate clinical documentation. [9]

Step 3: External Independent Medical Review

If PHS upholds the denial at the internal appeal level, you may request an external independent medical review through the New Mexico Office of Superintendent of Insurance (OSI). New Mexico requires insurers to comply with external review decisions. This step costs the patient nothing.

Step 4: Expedited Appeal for Urgent Cases

If your prescriber certifies that the standard timeline would seriously jeopardize your health or ability to regain maximum function, an expedited appeal must be decided within 72 hours. This pathway is most applicable when an adult patient with severe ADHD faces acute functional impairment at work or when a child is failing in school due to untreated symptoms.

Clinical Evidence Supporting Vyvanse for ADHD and BED

Insurance medical-necessity criteria are grounded in clinical evidence. Knowing the key trials strengthens your prescriber's PA and appeal letters.

ADHD Evidence

The key adult ADHD trial for Vyvanse (Adler et al., 2008, N=414) demonstrated statistically significant improvement on the ADHD Rating Scale (ADHD-RS) total score versus placebo at doses of 30 mg, 50 mg, and 70 mg daily over 4 weeks (P<0.001 for all doses). [10] A meta-analysis published in the Lancet Psychiatry (Cortese et al., 2018, N=10,068 participants across 81 trials) ranked lisdexamfetamine as the most effective stimulant for adult ADHD on standardized mean difference measures. [11]

For pediatric ADHD, Biederman et al. (2007, N=290, ages 6 to 12) showed Vyvanse produced significantly greater reductions in ADHD-RS scores compared to placebo across all doses tested (P<0.001). [12] This trial was central to the FDA's original 2007 approval. [1]

BED Evidence

The McElroy et al. Phase 3 trials (N=724 and N=422) published in JAMA Psychiatry established Vyvanse 50 mg and 70 mg as superior to placebo in reducing binge-eating days per week (P<0.001) and in achieving cessation of binge eating at 12 weeks. [13] These data supported the 2015 FDA approval for BED, the first pharmacotherapy indication for this diagnosis. [1]

Cardiovascular Monitoring Requirements

The FDA label includes a boxed warning for abuse potential and requires cardiovascular assessment before and during treatment. The American Heart Association recommends an ECG before initiating stimulants in children with a personal or family history of cardiac disease. [14] Prescribers submitting PA documentation to PHS should include current blood pressure and heart rate readings to satisfy safety-screening requirements. [1]

How Prescribers Can Optimize the PA Submission

A well-constructed prior authorization request dramatically reduces the chance of a first-pass denial. The following checklist is based on PHS's published PA criteria and standard managed-care documentation norms.

Documentation Checklist

• Confirm the diagnosis with a validated rating scale score, not just a clinical impression note
• List all stimulants tried previously, including dates, doses, duration, and reason for discontinuation (side effect, lack of efficacy, or contraindication)
• For BED: document DSM-5 criteria met, frequency and duration of binge episodes, and any prior psychological or dietary interventions
• Include the prescriber's DEA schedule II registration number on every PA form
• Attach the patient's current vital signs (blood pressure, heart rate, height, weight, BMI)
• Reference specific published evidence. Citing the Lancet Psychiatry meta-analysis [11] or the JAMA Psychiatry BED trials [13] in the medical necessity letter signals clinical rigor to the reviewing pharmacist

Peer-to-Peer Review Option

If the initial PA is denied by a PHS pharmacy reviewer, the prescriber has the right to request a peer-to-peer telephone review with a PHS medical director. This conversation, usually 10 to 20 minutes, allows the prescriber to explain clinical context not captured in the written form. Peer-to-peer reviews overturn roughly 50% of initial denials in managed-care settings, according to physician survey data published in JAMA Internal Medicine. [15]

The American Academy of Pediatrics policy statement on prior authorization notes that "the peer-to-peer review process is the most efficient single intervention available to clinicians seeking to overturn medically inappropriate denials." [16]

Medicare Part D and Vyvanse: A Separate Set of Rules

Some Presbyterian Health Plan members are enrolled in a Medicare Advantage plan with Part D drug benefit. Medicare Part D coverage of Vyvanse follows different rules than commercial coverage.

Part D Formulary Placement

CMS requires Part D plans to cover at least two drugs in each drug category. Stimulants used for ADHD were historically excluded from Part D formularies as non-covered "lifestyle" drugs, but a 2023 CMS policy clarification confirmed that FDA-approved medications for ADHD are covered when the indication is documented. [17] The generic lisdexamfetamine is more likely to appear at a preferred tier under Part D.

Extra Help / Low-Income Subsidy

Medicare beneficiaries who qualify for Extra Help (Low-Income Subsidy) pay no more than $4.50 for generic drugs and $11.20 for brand drugs per month (2024 benchmark amounts). [18] If you or a family member is on Medicare through a PHS plan and qualifies for Extra Help, the out-of-pocket cost for lisdexamfetamine may be negligible.

Alternatives If Vyvanse Remains Unaffordable or Uncovered

If PHS denies coverage and appeals are exhausted, practical alternatives exist.

Generic Lisdexamfetamine at Discount Pharmacies

Even without insurance, generic lisdexamfetamine 30 mg (30 capsules) may be available through GoodRx or Mark Cuban's Cost Plus Drugs at prices competitive with insured Tier 3 copays. Cost Plus Drugs lists generic lisdexamfetamine at transparent markup pricing without insurance. [19]

Other FDA-Approved ADHD Stimulants on Preferred Tiers

Formulary alternatives that PHS commonly places at Tier 1 include:

• Mixed amphetamine salts (generic Adderall): FDA-approved for ADHD, ages 3 and older [20]
• Methylphenidate extended-release (generic Concerta, Ritalin LA): FDA-approved for ADHD [21]
• Amphetamine extended-release oral suspension (Dyanavel XR): FDA-approved for ADHD, ages 6 and older [22]

If a specific clinical reason makes these alternatives unsuitable, that reason becomes the cornerstone of a step-therapy exception request.

Patient Assistance Programs

Takeda's patient assistance program (TAP) provides brand Vyvanse at no cost to uninsured or underinsured patients who meet income eligibility criteria (generally at or below 400% of federal poverty level). Applications are submitted through Takeda's patient assistance program portal. [8]